Skip to main content
Sandoz Group AG logo

Sandoz Group AG — Investor Relations & Filings

Ticker · SDZ ISIN · CH1243598427 LEI · 5493000JWK6XWFEUD320 SW Manufacturing
Open in API
Filings indexed 77 across all filing types
Latest filing 2025-07-01 Capital/Financing Update
Country CH Switzerland
Listing SW SDZ

About Sandoz Group AG

https://www.sandoz.com/

Sandoz Group AG is a global leader in generic and biosimilar medicines. The company's core activities involve the development, manufacturing, and distribution of off-patent pharmaceuticals to increase patient access to healthcare. Its business operates through two primary segments: Generics, which covers a wide range of small-molecule drugs, and Biosimilars, which are approved versions of original biologic medicines. Sandoz provides treatments for various diseases, including cancer and diabetes, and its product portfolio also includes key medicines such as antibiotics. The company's stated purpose is to pioneer access to medicines for patients worldwide.

Recent filings

Filing Released Lang Actions
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
Capital/Financing Update Classification · 99% confidence The document is explicitly titled "**MEDIA RELEASE**" and announces the start of construction for a new biosimilars production center, detailing investment figures and strategic rationale. It is a short, timely announcement about a significant corporate event (capital expenditure/investment) rather than a comprehensive periodic financial report (like 10-K or IR) or a transcript. This type of announcement, which is not a standard regulatory filing like 10-K, DEF 14A, or a specific financial report, best fits the category for updates on financing activities or major capital structure changes, which aligns with 'Capital/Financing Update' (CAP). While it discusses CapEx, it is primarily a press release announcing a major investment decision, making CAP the most appropriate fit over a general regulatory filing (RNS). The document length is moderate (6702 chars), but its content is clearly an announcement of a strategic financial action.
2025-07-01 English
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Regulatory Filings Classification · 100% confidence The document is titled 'Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules' and is labeled as a 'MEDIA RELEASE'. It announces the immediate availability of two new FDA-approved biosimilar products (WYOST® and Jubbonti®) in the US, detailing their indications, safety information (including contraindications and adverse reactions), and providing links to the full Prescribing Information. This type of announcement, which communicates a significant business event (product launch) via a press release format, is typically classified as a general Regulatory Filing (RNS) or sometimes an Earnings Release (ER) if it contained financial results. Since it is a specific, non-financial operational announcement (product launch/availability) that doesn't fit the specific definitions for ER, CT, or CAP, and it is not a formal report itself (like 10-K or IR), the most appropriate general regulatory category is RNS, as it is an 'Ad-hoc announcement' required by the exchange rules.
2025-06-02 English
Sandoz launches Pyzchiva® autoinjector, first commercially available in Europe for ustekinumab biosimilars
Regulatory Filings Classification · 99% confidence The document is explicitly titled "**MEDIA RELEASE**" and announces the European launch of a new product (Pyzchiva® autoinjector) by Sandoz, detailing its features, market context, and strategic importance. It includes standard press release elements like contact information, a disclaimer, and references. This type of announcement, which communicates significant business news (product launch/commercial availability) to the public and media, is best classified as an Earnings Release (ER) if it were quarterly results, but since it is a specific product/commercial announcement, it falls under the general category of a significant corporate announcement. Given the options, and recognizing that this is a primary communication of new business information rather than a formal regulatory filing (like 10-K or IR) or a report itself, it most closely aligns with the function of an Earnings Release (ER) which often serves as the primary vehicle for key periodic updates, or potentially a Regulatory Filing (RNS) if no better fit exists. However, since it is a 'Media Release' announcing commercial progress and product availability, and not a formal financial report or a specific regulatory filing type listed, the most appropriate category for a general, high-impact corporate announcement that isn't a formal financial report is often RNS (Regulatory Filings/General Announcement). But, if we interpret 'ER' broadly as 'Key Periodical/Business Update Announcement', it might fit. Given the strong emphasis on commercialization and market strategy, and the lack of a specific 'Product Launch Announcement' code, I will check the definitions again. ER is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. Therefore, the best fit among the remaining options for a general, non-financial, non-governance, non-legal, non-insider trade announcement is the fallback category, RNS (Regulatory Filings/General Announcement). The document length is substantial (9315 chars), so it is not an RPA. It is a full announcement, not just a notice of an attachment.
2025-05-21 English
Sandoz reports strong FY 2024 results and Q4 2024 sales
Earnings Release Classification · 98% confidence The document is titled 'Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules' and explicitly states it 'announced today results for the full year and net sales for the fourth quarter of 2024.' It contains detailed financial tables for the 'FULL-YEAR FIGURES' and 'FOURTH-QUARTER SALES,' including net sales, operating income, and core EBITDA margin, along with forward-looking guidance for 2025. This structure—a formal announcement detailing comprehensive annual and quarterly financial performance—is characteristic of an Earnings Release (ER) or, given the depth, potentially an Interim/Quarterly Report (IR) if the focus was solely on Q4. However, since it covers the 'full year' (FY 2024) results and includes forward guidance, it functions as the primary announcement of periodic financial results. Since the document is a press release announcing the results rather than the full, detailed regulatory filing (like a 10-K or a comprehensive IR document), 'Earnings Release' (ER) is the most appropriate classification for this initial, high-level results announcement. FY 2024
2025-03-05 English
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Regulatory Filings Classification · 95% confidence The document is titled 'Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules' and details the commercial launch of a new biosimilar drug, Pyzchiva®, in the US market. It includes key business updates, strategic context, quotes from management, and detailed safety/indication information for the drug, which is typical of a press release or a significant corporate event announcement. Since it is an immediate announcement of a major business event (product launch) and not a periodic financial report (like 10-K or IR), it fits best under the general category for significant, non-standard regulatory disclosures. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for an ad hoc announcement that doesn't fit a specific financial report type, although 'Earnings Release' (ER) is sometimes used for major business updates, this is specifically about a product launch, not periodic earnings. However, RNS is the designated fallback for general regulatory announcements not covered elsewhere. The document is substantial in length (17k+ chars) and contains detailed information, suggesting it is the primary announcement itself, not just a notice of publication (RPA). Therefore, RNS is the best fit as a general regulatory announcement.
2025-02-24 English
Francisco Ballester to retire; Peter Stenico appointed President Region International
Board/Management Information Classification · 100% confidence The document is an 'Ad hoc announcement' made pursuant to SIX Swiss Exchange Listing Rules. The content explicitly details the retirement of a senior executive (President Region International) and the appointment of his successor, including their new roles and effective dates. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management. Although it is a short announcement, it is the primary disclosure itself, not an announcement *about* another report, so RPA/RNS is less appropriate than the specific content classification. The document length (4679 chars) is sufficient for a primary announcement.
2025-02-03 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.